Trial Profile
A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 835726 (Primary) ; Cetirizine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GSK
- 22 Dec 2012 Planned number of patients added (54) as reported by European Clinical Trials Database record.
- 26 May 2012 Company UCB added to associations field as reported by European Clinical Trials Database record.
- 26 May 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.